AGP Executive Report
Last update: 7 hours agoDiabetes Breakthrough: CagriSema (cagrilintide + semaglutide) cut HbA1c and body weight across REIMAGINE phase 3 trials, pointing to a next-gen combo for type 2 diabetes. Opioid-Use Disorder Research: NIH began the first randomized, placebo-controlled Phase I trial of purified mitragynine (MG001) for opioid use disorder, moving kratom science into FDA-regulated testing. Public Health Tech: With vaccine trust slipping, Penn Engineering says AI chatbots can match traditional materials in tackling vaccine hesitancy, based on JAMA Network Open findings. AI Safety & Reliability: A new push argues AI must be treated as fallible in high-stakes work, stressing human verification and limits of confident outputs. Space & Biomanufacturing: NASA named the Artemis III crew, while UC San Diego explored using plants to produce plant-virus-based pharmaceuticals under space-like conditions. Industry & Infrastructure: Ingredion agreed to buy Tate & Lyle for about $5B, and Hubbell completed its NSI Industries acquisition to expand electrical components. STEM & Skills: Bulgaria’s dual education forum highlighted shortages in engineering and tech roles, while Southern Arkansas University launched a B.S. in Emergency Management for Fall 2026.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
